Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

7.91B

Market cap7.91B

Price-Earnings ratio

-9.83

Price-Earnings ratio-9.83

Dividend yield

—

Dividend yield—

Average volume

2.25M

Average volume2.25M

High today

$64.68

High today$64.68

Low today

$60.87

Low today$60.87

Open price

$62.24

Open price$62.24

Volume

2.11M

Volume2.11M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$29.31

52 Week low$29.31

Stock Snapshot

As of today, Cytokinetics(CYTK) shares are valued at $63.98. The company's market cap stands at 7.91B, with a P/E ratio of -9.83.

On 2026-03-11, Cytokinetics(CYTK) stock moved within a range of $60.87 to $64.68. With shares now at $63.98, the stock is trading +5.1% above its intraday low and -1.1% below the session's peak.

Trading volume for Cytokinetics(CYTK) stock has reached 2.11M, versus its average volume of 2.25M.

The stock's 52-week range extends from a low of $29.31 to a high of $70.98.

CYTK News

TipRanks 9h

Top Cytokinetics Executives Quietly Cash In on Major Stock Sales

New insider activity at Cytokinetics ( (CYTK) ) has taken place on March 10, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful inve...

Simply Wall St 2d

A Look At Cytokinetics Valuation After Analyst Updates And Myqorzo Launch

Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as in...

Nasdaq 2d

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

Key Points 15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026. T...

Analyst ratings

86%

of 21 ratings

Buy

85.7%

Hold

14.3%

Sell

More CYTK News

Simply Wall St 4d

How Cytokinetics’ ESOP Shelf Offering and Q4 Losses Could Reshape the CYTK Long-Term Narrative

In late February 2026, Cytokinetics filed a US$47.17 million shelf registration for 750,000 common shares tied to an ESOP-related offering and reported fourth-q...

TipRanks 5d

Cytokinetics Earnings Call Marks High-Stakes Launch Phase

Cytokinetics ((CYTK)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data an...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.